Ensysce Biosciences Files 8-K on Security Holder Vote

Ticker: ENSCW · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1716947

Ensysce Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyEnsysce Biosciences, INC. (ENSCW)
Form Type8-K
Filed DateNov 21, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

TL;DR

Ensysce Biosciences is having a shareholder vote soon, details to follow.

AI Summary

Ensysce Biosciences, Inc. filed an 8-K on November 21, 2024, to report on the submission of matters to a vote of its security holders. The filing indicates that a vote will be held, but does not specify the proposals or the outcome.

Why It Matters

This filing signals an upcoming shareholder vote, which could lead to significant corporate actions or changes that may impact the company's future direction and stock value.

Risk Assessment

Risk Level: medium — The filing indicates a shareholder vote is upcoming, which could lead to changes in corporate governance or strategy, but lacks specific details on the proposals.

Key Players & Entities

FAQ

What is the specific date of the security holder meeting?

The filing does not specify the exact date of the security holder meeting, only that it is related to matters submitted for a vote as of November 21, 2024.

What specific matters are being submitted to a vote of security holders?

The filing does not detail the specific proposals or matters being submitted for a vote by security holders.

What is the purpose of this 8-K filing?

The purpose of this 8-K filing is to report the submission of matters to a vote of security holders, as required by SEC regulations.

Has Ensysce Biosciences, Inc. undergone any recent name changes?

Yes, Ensysce Biosciences, Inc. was formerly known as Leisure Acquisition Corp., with a name change date of September 13, 2017.

Where is Ensysce Biosciences, Inc. headquartered?

Ensysce Biosciences, Inc. is headquartered at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, 92037.

Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-11-21 16:15:24

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 21, 2024 Ensysce Biosciences, Inc. By: /s/ Lynn Kirkpatrick Name: Dr. Lynn Kirkpatrick Title: President and Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing